Oral squamous cell carcinoma (OSCC) is among the deadliest oral cancers, largely due to late diagnoses and limited therapeutic options. 

Researchers have discovered a way to make the immune system’s T cells significantly more effective at fighting cancer. By blocking a protein called Ant2, they were able to reprogram how these cells consume and generate energy—essentially rewiring their internal power supply. This shift makes T cells more active, resilient, and better at attacking tumors. The findings open the door to new treatments that could strengthen the body’s own immune response, offering a smarter, more targeted approach to cancer therapy.

Australian researchers have discovered a promising new strategy to suppress the growth of aggressive and hard-to-treat cancers by targeting a specialised molecular process known as ‘minor splicing’. The study from WEHI, published in EMBO Reports, shows that blocking minor splicing can markedly slow tumour growth in liver, lung and stomach cancers, while leaving healthy cells largely unharmed.  

UZ Brussel has become the first hospital in the world to surpass 100 robot-assisted lymphovenous bypass surgeries for patients with lymphedema. This cutting-edge microsurgical procedure offers a minimally invasive treatment option for individuals suffering from painful limb swelling—often a side effect of cancer treatments such as breast or prostate surgery.

Neutrophils, once considered simple foot soldiers of innate immunity, are now recognized as complex players in cancer.

Liver metastasis is a life-threatening complication of colorectal cancer (CRC), yet its molecular underpinnings remain elusive.

Researchers at Nagoya University in Japan have developed a lipid nanoparticle that delivers mRNA to cells five times more effectively. By attaching a sulfur-containing ring structure—a cyclic disulfide—to lipid molecules, they found that significantly more mRNA can escape from cell components that normally destroy genetic material. When tested as a cancer vaccine in mice, the new delivery system stopped tumor growth. The study, published in the journal RSC Medicinal Chemistry, demonstrates the first successful use of cyclic disulfide-containing lipids to improve mRNA delivery in animals and suppress tumor growth.

The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at Sylvester Comprehensive Cancer Center.

Researchers at EPFL have discovered how the structure of DNA packaging in cells determines which proteins can interact with the key tumor suppressor p53.